Purine derivatives as sik-3 inhibitors
AssigneeRhizen Pharmaceuticals SA
InventorsPrashant K. BHAVAR, Srikant VISWANADHA, SRIDHAR VEERARAGHAVAN, Babu GOVINDARAJULU, Swaroop Kumar Venkata Satya VAKKALANKA
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel inhibitors of salt-inducible kinase-3 (SIK3), methods of preparing them, pharmaceutical compositions containing them and methods for the treatment and/or prevention of kinase mediated diseases or disorders using them.
Claims21
A compound selected from (RS)-3-(3-fluorophenyl)-2-(1-((8-hydroxy-9H-purin-6-yl)amino)propyl)-4H-chromen-4-one and pharmaceutically acceptable salts thereof.
A compound selected from(S)-3-(3-fluorophenyl)-2-(1-((8-hydroxy-9H-purin-6-yl)amino)propyl)-4H-chromen-4-one and pharmaceutically acceptable salts thereof.
A compound selected from
- (RS)-3-(3-fluorophenyl)-2-(1-((8-hydroxy-9H-purin-6-yl)amino)propyl)-4H-chromen-4-one,
- (S)-3-(3-fluorophenyl)-2-(1-((8-hydroxy-9H-purin-6-yl)amino)propyl)-4H-chromen-4-one, and
- (R)-3-(3-fluorophenyl)-2-(1-((8-hydroxy-9H-purin-6-yl)amino)propyl)-4H-chromen-4-one,
- and pharmaceutically acceptable salts thereof.
10-11. (canceled)
Dependencies are inferred from the claim text.